Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18 years of age or older~* History of RLS symptoms for at least 15 nights/month~* Documented RLS symptoms, using the 7-day RLS Symptom Record, for at least 4 of the 7 consecutive evenings/nights during the night~* Total RLS severity score of 15 or greater on the International RLS (IRLS) Rating Scale at Visit 1 and at Visit 2~* Discontinuation of dopamine agonists and/or gabapentin , or other treatments for RLS (e.g. opioids, benzodiazepines) at least 2 weeks prior to Baseline~* If taking any prescription medication, therapy must have been stabilized for at least 3 months prior to Screening with no anticipated changes for the duration of the study~* Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use a highly effective method for avoiding pregnancy~* Body mass index of 34 or below~* Estimated creatinine clearance of ≥60 mL/min~* Provides written consent in accordance with all applicable regulatory requirements~Exclusion Criteria:~* History of a sleep disorder that may affect the assessment of RLS~* History of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment~* Neurologic disease or movement disorder~* Other medical conditions or drug therapy that could affect RLS efficacy assessments or may present a safety concern~* Have clinically significant or unstable medical conditions~* Have active suicidal plan/intent or has had active suicidal thoughts in the past 6 months; has a history of suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1838262 600 mg (Type: ACTIVE_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM
- GSK1838262 450 mg (Type: ACTIVE_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM
- GSK1838262 300 mg (Type: ACTIVE_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM
- GSK1838262 placebo match (Type: PLACEBO_COMPARATOR): Once-daily dose with food in the evening at approximately 5 PM

Based on this trial design, predict the completion outcome and termination type (if applicable).